CION Ameerpet
Clinical trials & access
What Happens When a Trial Ends? — The Continued-Access Question, Answered Before You Enrol
For many Indian families a registered clinical trial is the only way immunotherapy becomes reachable at all — which is exactly why the end of the study period lands so hard, and why almost nobody is told about it in advance. Study treatment runs for the period written into the protocol and no longer. This page sets out plainly whether treatment continues, what continued access actually means, what to do if your disease was controlled during the study, and the eight questions to ask before you sign the consent form. It is information only: nothing here recruits anyone, and continued access is never assured.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Treatment does not continue by default — The study supplies the investigational drug for the treatment period in its protocol, and no longer. Many studies make no post-trial provision at all, and that is the common outcome.
- Continued access has a name, and a paragraph in your consent form — An extension study, sponsor supply, or a compassionate-use application to CDSCO. Ask which, if any, applies to your study — in writing, before you join.
- If your scans were stable, start the conversation early — Three to four months before the last planned dose, not in the week it arrives. Extension studies have their own approvals, criteria and timelines.
- Information, not recruitment — Nothing here is an offer of a place on a study or of any medicine, no benefit is claimed for any investigational treatment, and access after a study is never assured.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The direct answer
Do You Keep Getting Treatment When a Clinical Trial Ends?
Not automatically. A study supplies the investigational drug for the treatment period written into its protocol, and no longer. What happens next depends on why the study ended, on what your consent document says, and on whether the sponsor runs a continued-access route at all. Ask for that answer in writing before you enrol.
This is the question families discover far too late — usually in the month the last dose falls, when there is no time left to plan. For a large number of Indian families a registered trial is the only route by which immunotherapy becomes reachable at all, which makes the ending of it a financial event as much as a clinical one. The honest position is that a trial is a defined episode of treatment with a defined stop, and the stop should be planned for on the day you sign the consent form.
| Why your treatment ended | What it means | What usually happens next |
|---|---|---|
| You completed the planned treatment period | The protocol sets a fixed number of cycles or a maximum duration, and you reached it | Study treatment stops on schedule. Follow-up visits continue. Anything beyond that depends on whether an extension study or a sponsor supply route exists |
| Your disease progressed on the study | The protocol’s stopping rule was met | Study treatment stops. You return to your treating oncologist for the next approved line, which should already have been discussed |
| You had a side effect that required permanent discontinuation | The protocol requires stopping for certain immune-related and other toxicities | Study treatment stops. Safety follow-up continues, and management moves to your treating team |
| You chose to withdraw | You may withdraw at any time, for any reason | Study treatment stops. You keep your right to standard treatment at that centre; withdrawing does not cost you your care |
| The sponsor stopped the study early | Funding, a regulatory decision, or an interim analysis | Treatment stops for everyone. Participants must be told, and the sponsor and ethics committee are expected to set out what happens next |
| The study finished and the molecule was later approved | CDSCO approval for your indication may follow, months or years afterwards | The drug may become purchasable. Approval is not the same thing as affordability, and it is not continued access |
This page is information only. Nothing here recruits anyone into a study, nothing here is an offer of a place or of any medicine, and no benefit is claimed for any investigational treatment — a treatment under study is by definition one whose benefit is not yet established.
Did you know?
What happens after the study is meant to be written into the informed consent document you sign at the start. ICMR’s National Ethical Guidelines and the Declaration of Helsinki both address post-trial provisions, and the consent process is where they are supposed to reach you. So the single most useful thing you can do about the ending of a trial is to read that paragraph before you join — and, if it is vague, to ask for it to be explained in writing.
The term to know
What Is Continued Access After a Clinical Trial?
Continued access is any arrangement that lets you keep receiving a study treatment after your part in the study ends. It is not one thing. It may be an open-label extension study, a sponsor’s post-trial supply, a compassionate-use application to CDSCO, or nothing at all. It is never automatic.
| Route | What it is | Who decides | What it typically costs your family |
|---|---|---|---|
| Open-label extension study | A separate, separately registered study that continues to supply the treatment to participants from the original study | The sponsor, a registered ethics committee and CDSCO. You must meet its criteria and consent again | The study drug is usually supplied. Day care, routine monitoring, scans and travel commonly stay with you. Indicative, as of August 2026 |
| Post-trial supply by the sponsor | The sponsor continues to provide the drug to a named participant outside any study | The sponsor, case by case. There is no application you can make yourself | Usually the drug is provided; everything around it stays with you. Indicative, as of August 2026 |
| Compassionate use / named-patient supply | The New Drugs and Clinical Trials Rules, 2019 contain provisions under which a sponsor may apply to CDSCO to supply a new drug for a named patient with a serious condition and no satisfactory alternative | CDSCO, on a sponsor’s application, with ethics committee involvement | Varies. It is a regulatory route, not a purchase route, and it cannot be assumed |
| Switching to an approved treatment | Where the same molecule, or an approved alternative, is licensed and marketed in India for your indication | Your treating oncologist, with you | The standard cost of that treatment, which is often the reason the trial route was chosen. Indicative, as of August 2026 |
| The next standard line | Returning to approved treatment appropriate to where your disease now is | Your treating oncologist, with you | As for the regimen chosen. Insurance and scheme cover apply as they normally would |
| No provision at all | Many studies make no post-trial arrangement. This is common and it is not a failure of your study team | Decided in the protocol, before you ever enrolled | Nothing continues. Plan for this outcome, because it is the most likely one |
None of these routes is assured, and none of them can be bought. Anyone offering an investigational medicine outside a registered study or a proper regulatory route is not offering you a trial, whatever it is called. Continued access to an investigational drug is also a different question from using an already-approved drug outside its licensed indication — that is covered in Off-Label Use of Immunotherapy: Is It Allowed?
The hardest ending
What If the Trial Treatment Was Working for You?
This is the ending families find hardest. Scans stable, symptoms settled, and then the protocol’s treatment period simply runs out. A response during a study does not entitle you to continued supply, and no study promises one. Start the conversation three to four months before your last planned dose, not after it.
- Raise it early, and in writing — put the question to the principal investigator and the study coordinator well before the final cycle. An extension study, where one exists, has its own timelines, its own approvals and its own eligibility criteria, and none of that can be arranged in a fortnight.
- Check whether stopping was always the plan — for some checkpoint-inhibitor regimens a fixed treatment duration is written into the protocol by design. Stopping at that point is the plan, not a withdrawal of care, and monitoring continues afterwards. Ask which of the two situations you are in.
- Ask about re-treatment rules — some protocols allow a participant who completed treatment to be treated again if the disease progresses later. Ask whether yours does, what would qualify you, and how long that option stays open.
- Get your data out while the study team is still active — which arm you were on once unblinding has happened, every dose and date, scan reports, and every adverse event recorded. Your treating oncologist cannot plan the next step without it, and it is far harder to obtain a year later.
- Keep your own oncologist in the loop throughout — the study team’s responsibility ends with the study. Your treating oncologist’s does not, and they are the person who will decide what follows.
- Have the money conversation in parallel — if the molecule is approved and purchasable in India, ask for an indicative cost early rather than in the week treatment stops, and check what insurance or a state scheme would cover. Indicative, as of August 2026.
Nothing on this page is recruitment, and nothing on it is an offer. Access to an investigational medicine after a study is decided by the sponsor, the ethics committee and CDSCO. No place on any study, extension study or supply programme is offered here, and enrolment in anything is never assured.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Ask the Post-Trial Question Before You Sign, Not After
A medical oncologist can read the consent document with you and say plainly what happens when the study treatment stops.
Before you sign
What Should You Ask About Post-Trial Access Before You Enrol?
Eight questions, asked before the consent form is signed, and answered in writing. What is the maximum treatment duration? What does the consent document promise? Is there an extension study? Who supplies the drug afterwards, and who pays? A study team expects these questions. Asking them is not distrust.
-
How long is treatment, at most?
Ask for the maximum number of cycles or months written into the protocol, then write down the calendar date your last planned dose falls on.
-
What does the consent document say about post-trial access?
Ask for the paragraph by name, read it before signing, and take the document home. You are entitled to do that.
-
Is there an open-label extension study?
Ask whether one exists, whether you would have to meet fresh criteria, and whether you would have to consent again.
-
Who supplies the drug after my last dose, if anyone?
Sponsor, hospital, or nobody. Get a named answer rather than a reassurance.
-
Who pays for what after the study ends?
Day care, monitoring blood work, response scans and travel. Ask for an itemised split; indicative, as of August 2026.
-
What happens if my disease progresses during the study?
Ask what the study does for you at that point and who takes over your treatment decisions.
-
What happens if the sponsor stops the study early?
Ask how participants are told, by whom, and what the plan for you would be.
-
What is my own oncologist's plan B?
Ask your treating oncologist, before you enrol, what the approved next line would be if nothing continues after the study.
Ask all eight at the screening visit, while you still have the option of not joining. If the study site is in another city, remember that the follow-up visits after treatment ends are in that city too — Travelling to Another City for a Clinical Trial sets out what that commitment actually involves for a family.
The timeline
What Happens in the Weeks After Your Last Trial Dose?
Your part in a study does not end with the last infusion. There is an end-of-treatment visit, a safety follow-up window, and often long-term follow-up by telephone. Handover to your treating oncologist belongs in this period. Ask for your records in writing while the study team is still active.
| Stage | Typically when | What happens | What to ask for |
|---|---|---|---|
| End-of-treatment visit | Within days to a few weeks of the last dose | Clinical review, blood work, sometimes imaging, and formal closure of the treatment phase | A written summary of your participation, including dates and doses |
| Safety follow-up window | Commonly around 30 to 90 days after the last dose, as the protocol defines | Adverse events are still collected. Immune-related effects can appear or persist after treatment has stopped, which is why this window exists | Who to call, in hours and out of hours, and for how long that number stands |
| Response assessment | As the protocol schedules it | Imaging to document where the disease stands at the end of treatment. At CION, response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION | A copy of the images and the radiologist’s report for your own file, taken at the time of the scan |
| Unblinding | Usually after the whole study closes, not on your last dose | You are told which arm you were on. In a blinded study nobody at the site can tell you before this | The arm allocation in writing. Your next oncologist needs to know what you actually received |
| Long-term follow-up | Months to years, often by telephone | The study continues to collect outcome data. This is data collection, not treatment | Confirmation of what is still expected of you and for how long |
| Handover | As soon as study treatment stops | Your treating oncologist resumes the plan and decides what follows | The complete record: doses, dates, scans, adverse events, and the arm you were on |
Nothing in this schedule commits a study to giving you more treatment. It is documentation and safety follow-up, and it is valuable for exactly that reason. Treat the handover as the real deliverable of the ending, because it is the part that shapes what your own oncologist can do next.
Before your last planned dose
Plan the Handover While the Study Team Is Still Active
Bring your consent document, your scan reports and your treatment dates. We will tell you what to ask for now — and what your approved options are afterwards.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
What Happens When a Trial Ends: Your Questions Answered
Do you keep getting treatment when a clinical trial ends?
Not automatically. A study supplies the investigational drug for the treatment period written into its protocol, and no longer than that. When that period ends, when your disease progresses, when a side effect forces permanent discontinuation, or when the sponsor stops the study early, study treatment stops. What follows depends on three things: what your consent document says about post-trial access, whether the sponsor runs an extension study or a named-patient supply route, and what approved treatment your own oncologist recommends next. None of those is automatic and none is assured. Ask for the answer in writing before you enrol, not in the month your last dose falls.
What is continued access after a clinical trial?
Continued access is any arrangement that lets you keep receiving a study treatment after your own part in the study ends. It is not a single thing. It may be an open-label extension study, which is a separate registered study you must qualify for and consent to again. It may be post-trial supply by the sponsor to a named participant. It may be a compassionate-use application: the New Drugs and Clinical Trials Rules, 2019 contain provisions under which a sponsor may apply to CDSCO to supply a new drug for a named patient with a serious condition and no satisfactory alternative. Often there is no provision at all. You cannot buy your way into any of these routes.
What happens if the trial treatment was working for you?
This is the ending families find hardest, and the one they discover too late. Scans stable, symptoms settled, and then the protocol's treatment period simply runs out. A response during a study does not entitle you to continued supply, and no study promises one. Start the conversation three to four months before your last planned dose. Ask the principal investigator whether an extension study exists, whether the sponsor supplies the drug to participants afterwards, and whether re-treatment is allowed if the disease progresses later. For some checkpoint-inhibitor regimens a fixed treatment duration is written into the protocol by design, so stopping at that point is the plan rather than a withdrawal of care.
What should you ask about post-trial access before you enrol?
Ask eight questions and get the answers in writing. What is the maximum treatment duration in the protocol, and what date does my last planned dose fall on? What exactly does the consent document say about access after the study? Is there an open-label extension study, and would I need to qualify and consent again? Who supplies the drug after my last dose, if anyone? Who pays for day care, monitoring, scans and travel afterwards, indicative as of August 2026? What happens if my disease progresses during the study? What happens if the sponsor stops the study early? And what is my own oncologist's plan B if nothing continues?
What happens in the weeks after your last trial dose?
Your part in a study does not end with the last infusion. There is an end-of-treatment visit, usually within days to a few weeks. There is a safety follow-up window, commonly around 30 to 90 days depending on the protocol, during which adverse events are still collected; immune-related effects can appear or persist after treatment has stopped. There is often long-term follow-up by telephone for months or years. Unblinding usually happens after the study closes rather than on your last dose. Use this period to ask for your full record in writing: which arm you were on, doses, dates, scan reports and adverse events. Your treating oncologist will need all of it.
Does CION arrange continued access to an investigational drug?
No, and this page is information rather than recruitment. Access to an investigational drug after a study is decided by the sponsor, the ethics committee and CDSCO through the routes described above; nothing here is an offer of a place on a study or of any medicine. CION Cancer Clinics administers approved immunotherapy as day care at its centres, and response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION. CION does not provide CAR-T or other cell therapies, so where a cell-therapy study is what ended, that is a referral to a centre that runs one. What a consultation can do is read your consent document and reports with you and set out the approved options that remain.